ReviewFrontiers in endocrinology2025
Application progress of magnetic resonance imaging in thyroid associated ophthalmopathy.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A Pilot MRI Study of Upward Gaze-Induced Intraocular Pressure Elevation in Thyroid Eye Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Interpretable machine learning for severity classification of thyroid eye disease using orbital anatomical features.Frontiers in medicine · 2026Article
- SPECT/CT imaging in thyroid eye disease: an emerging role in assessing sub-clinical activity.Frontiers in ophthalmology · 2026Review
- Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations.Frontiers in medicine · 2026Article
- Advancements and challenges of ultrasound imaging in the management of thyroid-associated ophthalmopathy.World journal of radiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid associated ophthalmopathy (TAO) is an autoimmune orbital disease associated with thyroid dysfunction, which may significantly impact the appearance and quality of life of patients. The course of TAO includes active stage and inactive stage, and the treatment methods are different in different stages. The clinical activity score is often used to evaluate the activity of TAO, but it is easy to be affected by subjective factors because it is based on the symptoms and signs of patients. Magnetic resonance imaging (MRI) can evaluate the postorbital tissue structure of TAO more objectively and accurately. A variety of MRI modalities have been used in the diagnosis and treatment of TAO. This article mainly summarizes the application of MRI in diagnosing TAO, assessing its activity, predicting treatment efficacy, and evaluating therapeutic outcomes, thereby providing clinicians with additional evidence-based options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.